National Bank of Canada’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

National Bank of Canada’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-41	Closed	-$93	–	2872
2024 Q1	$93	Sell	41 -2	-5%	-$12	﹤0.01%	2672
2023 Q4	$301	Hold	43	–	–	﹤0.01%	2623
2023 Q3	$383	Hold	43	–	–	﹤0.01%	2668
2023 Q2	$909	Hold	43	–	–	﹤0.01%	2564
2023 Q1	$1.15K	Hold	43	–	–	﹤0.01%	2514
2022 Q4	$1.5K	Hold	43	–	–	﹤0.01%	2535
2022 Q3	$10K	Buy	43 +35	+438%	+$8.6K	﹤0.01%	2191
2022 Q2	$2K	Hold	8	–	–	﹤0.01%	2648
2022 Q1	$2K	Hold	8	–	–	﹤0.01%	2736
2021 Q4	$1K	Buy	+8	New	+$1.55K	﹤0.01%	2782

Other funds holding EIGR

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

National Bank of Canada's EIGR Position: Q2 2024 in Review

National Bank of Canada sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2024, closing a stake of 41 shares — an estimated $93 sold.

National Bank of Canada first reported a position in EIGR in Q4 2021 and held it in 10 quarters. The position peaked at $10K in Q3 2022. 2 funds tracked by Wall St. Rank hold EIGR as of Q2 2024.

National Bank of Canada reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
National Bank of Canada sold 41 Eiger BioPharmaceuticals, Inc. shares in Q2 2024, an estimated $93.
National Bank of Canada first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2021 and held it in 10 quarters.
National Bank of Canada's Eiger BioPharmaceuticals, Inc. position peaked at $10K in Q3 2022.
2 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2024.

Based on National Bank of Canada's 13F filing for Q2 2024, filed 2 Aug 2024.